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Human adrenomedullin (ADM), a 52-amino acid peptide, belongs to the calcitonin/calcitonin gene-related pep-
tide (CGRP)/amylin peptide family. ADM acts as a multifunctional regulatory peptide and is upregulated in re-
sponse to hypoxia. Previous microarray studies have found increased ADM gene (ADM) expression in peripheral
blood cells of patients with stroke, however, it is unknown if an increased ADM level is correlated with severity of
human ischemic stroke. This study investigated ADM expression in peripheral blood leukocytes (PBL) of healthy
controls and subjects at day 1, week 1 and week 3 postacute ischemic stroke using rtPCR methodology. We
found that ADM expression was significantly upregulated on the first day of stroke compared to the healthy
subjects and the disease controls; the levels remained elevated for up to week 3. Further, ADM expression at
day 1 was correlated with stroke severity measured by the National Institute of Healthy Stroke Scale (NIHSS),
the modified Barthel Index (mBI) and the modified Rankin Scale (mRS). This could indicate that ADM expression
level is related to the severity of tissue damage. We suggest that increased ADM expression in PBL after acute
ischemic stroke is most likely to indicate that these cells have been subjected to hypoxia and that the magnitude
of expression is likely to be related to the volume of hypoxic tissue. Hypoxia can affect lymphocytes function
and could affect the immune response to stroke. The correlation of ADM expression level with the measures of
stroke severity implicates ADM – a potential blood bio-marker in studies of ischemic stroke.
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Introduction
Acute ischemic stroke is resultant from a sudden loss of
blood supply to focal areas of the brain. This leads to
cell death and local inflammation. Systemic responses
induced by ischemic stroke include modulation of the
immune system and alteration of gene expression in pe-
ripheral blood cells [1–3].
Adrenomedullin (ADM) is a 52 amino acid peptide,
belongs to the calcitonin/CGRP (calcitonin gene-related
peptide)/amylin peptide family. The ADM gene (ADM)
is located on chromosome 11 with a single locus [4].
ADM was originally isolated from human pheochromo-
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cytomas [5,6]. The ADM product exists in plasma and
a variety of tissues including blood vessels, heart and
lungs [7], however, measurement of the ADM protein
presents difficult due to a short half-life [8,9]. The bio-
logical activities of ADM has been investigated inten-
sively and include vasodilation, diuresis and natriure-
sis, positive inotropic effect, inhibition of endothelial cell
apoptosis, induction of angiogenesis, inhibition of car-
diomyocyte apoptosis, suppression of aldosterone pro-
duction, anti-inflammatory activity and antioxidant ac-
tivity [7].
ADM has been shown to be protective in ischemic
stroke. In a rat model, postischemic infusion of ADM
has been shown to protect against ischemic stroke by
inhibiting apoptosis and promoting angiogenesis [10].
ADM also plays important autocrine and paracrine
roles by regulating circulation and endothelial blood-
brain barrier functions [11]. Evidence from cell culture
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protective effects against vascular injury, including the
effects of oxidative stress [7]. Increased expression of
both ADM and a component of the ADM receptor,
Calcitonis-receptor-like receptor (CRLR), have been
found in cultured endothelial cells under hypoxic con-
ditions [7,11]. Treatment with ADM has been thought
to limit infarct size through mitochondrial KCa in PKA
signaling pathways [12].
A study using the microarray technique examined
gene expression profile in peripheral blood mononu-
clear cells of human acute ischemic stroke and showed
thatADM level was increased [13]. Further studies have
shown that ADM level is regulated by hypoxia-inducible
factor-1 in other diseases or tissues [14–16].
It is unknown if endogenous ADM levels are cor-
related with stroke severity postischemia. Our study
aimed to investigate ADM expression in peripheral
blood leukocytes (PBL) in patients at day 1, week 1 and
week 3 after acute ischemic stroke using rtPCR, and cor-
relate this with stroke severity, as measured by the most
common stroke severity scales the National Institute of
Healthy Stroke Scale (NIHSS) (http://www.ninds.nih.
gov/doctors/NIH Stroke Scale.pdf) [17] and with dis-
ability using the modified Barthel Index (mBI) and the
modified Rankin Scale (mRS) [18–21]. The NIHSS
measures the impairment of a patient’s ability caused by
stroke using 42 scores, with a low score correlating to
lesser symptoms and a high score correlating with more
severe stroke symptoms. The mBI is a modification of
the original Barthel Index initially developed in 1965
[18,19]. The mBI measures the daily performance of
patients in a range from 0–100, with high score showing
better performance. The mRS measures patient’s inde-
pendence, not performance, in 6 grades, from 0 to 5,
with low score corresponding to better symptoms.
Our results indicated that the ADM RNA level at the
initial stroke period is correlated with severity as com-
pared to healthy controls and the subjects with motor
neurone disease (MND), and suggests that ADM ex-
pression level at day 1 poststroke may be a potential
blood bio-marker in studies of ischemic stroke.
Material and methods
Participants
The study design and protocol was approved by the
Human Research Ethics Committees of the Royal Bris-
bane and Women Hospital, the Wesley Hospital and the
Medical Research Ethics Committees of the University
of Queensland. All participants provided informed con-
sent. Detail of patients and controls are summarized in
Table 1.
Stroke patients were recruited from the Royal Bris-
bane and Women Hospital and Wesley Hospital, Bris-
bane, Australia, between August 2008 and December
2011. Ischemic stroke was diagnosed on clinical history,
presence of focal neurological signs and symptoms, and
by MRI or CT brain scans. The strokes were classified
according to the Oxfordshire Stroke Classification [22]
into total anterior circulation infarcts (TACI), partial
anterior circulation infarcts (PACI), posterior circula-
tion infarcts (POCI) and lacunar infarcts (LACI). Pa-
tient stroke severity was evaluated on day 1, week 1 and
week 3 by NIHSS, mBI and mRS. Demographic data
was collected from the patient or their family members.
Blood was collected from stroke subjects at three time
points: day 1, 7–10 d (referred as Week 1 in the text)
and 3–6 weeks (referred as Week 3 in the text) after
stroke. We also recruited age and sex matched healthy
subjects and the patients with MND, recruited from the
MND clinic, as a disease control. Blood from these sub-
jects was collected only once. In total, samples from
44 patients with acute ischemic stroke, 19 healthy sub-
jects and 27 patients with MND were studied (Table 1).
Table 1. General condition of participants.
Acute ischemic stroke
Total stroke Healthy MND Disease
day 1 week 1 week 3 patients controls patients
Number
Total 24 37 34 37 19 28
Female 10 13 12 13 11 10
Male 14 24 22 24 8 18
Median age in years (range) 67.5 (32–85) 65 (27–87) 67.5 (32–88) 66.7 (27–88) 60.5 (24–95) 62.8 (36–76)
Hypertension N (%) 17 (71%) 23 (62%) 21 (62%) 23 (62%) 4 (21%) N.A.
Hyperlipidemia N (%) 12 (50%) 15 (41%) 14 (41%) 15 (41%) 2 (11%) N.A.
Diabetes N (%) 1(4.2%) 3 (8%) 3 (8%) 3 (8%) 0 (0%) N.A.
Smoking N (%) 15 (63%) 20 (54%) 20 (59%) 2 (59%) 2 (11%) N.A.
NIHSS median (range) 6.5 (0–24) 4.5 (0–18) 3 (0–19) 4.7 (0–24) N.A. N.A.
mBI median (range) 26.5 (0–97) 80.5 (0–100) 95 (0–100) 81 (0–100) N.A. N.A.
mRS median (range) 4 (2–5) 3 (1–5) 2 (1–5) 3 (1–5) N.A. N.A.
N.A. = not applicable
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Not all stroke patients provided blood samples at all 3
time points: 24 patients provided blood samples on day
1 after onset, 37 patients at week 1 and 34 patients at
week 3.
RNA extraction and ﬁrst strand cDNA
synthesis
Peripheral blood (2.5 ml) was collected into PAX-
geneTM Blood RNA tubes (Qiagen, Australia). The
blood RNA tubes were left at room temperature for 8 h
and then kept in −20◦C until RNA extraction (up to
36 months). RNA was extracted using a PAXgeneTM
Blood RNA Extraction Kit (PreAnalytiX, Qiagen, Aus-
tralia). RNA concentration was determined by the Nan-
odrop and RNA quality was determined using the Expe-
rionTM Automated Electrophoresis System (Bio-Rad,
Australia). All RNA samples used in this study had a
RNA quality index >7.
First strand cDNA was synthesized using an RT2
Easy first strand synthesis kit (PreAnalytiX, Qia-
gen, Australia). The final concentration of extracted
RNA samples was adjusted to 125 ng/μl. First strand
cDNA synthesis reactions were conducted with 8 μl of
125 ng/μl RNA samples, according to themanufacture’s
protocol (SABiosciences, Qiagen, Australia). Briefly the
samples were incubated at 42◦C for 5 min, followed by
incubation at 42◦C for 15 min and 95◦C for 5 min for
the reverse transcription.
qPCR array
Customized qPCT plate and the primers for ADM gene
were prepared by SABiosciences (Qiagen, Australia).
SYBER greenmaster mix including Taq polymerase was
activated at 95◦C for 10 min. Thermal cycling was done
using an iQ5 qPCR machine (Bio-Rad. Australia) with
40 cycles at 95◦C for 15 s and 60◦C for 1 min. β-actin
was used to normalize the sample loading. The thresh-
old value of each reaction and the quality of controls
were analyzed using Web-based software, supplied by
SABiosciences.
Quantiﬁcation of ADM serum level
A commercial enzyme linked immune-sorbent assay kit
(ADM EIA kit, Phoenix pharmaceuticals, Inc, Califor-
nia, USA) was used to detect the serum level of ADM.
The sequence of the kit detected was Tyr – Arg – Gln –
Ser – Met – Asn – Asn – Phe – Gln – Gly – Leu – Arg
– Ser – Phe – Gly – Cys – Arg – Phe – Gly – Thr – Cys
– Thr – Val – Gln – Lys – Leu – Ala – His – Gln – Ile –
Tyr – Gln – Phe – Thr – Asp – Lys – Asp – Lys – Asp
– Asn – Val – Ala – Pro – Arg – Ser – Lys – Ile – Ser –
Pro – Gln – Gly – Tyr – NH2. The serum samples were
tested in a serial dilution in preliminary experiments. As
the level of ADM was low, we decided to use undiluted
serum in the experiment. A standard curve and negative
controls were included in each plate. a 50 μl of undi-
luted serum from each patient and healthy control was
added in triplicate. The assay was carried out according
to manufacturer’s instruction.
Flow cytometry of PBL
Cell populations (T cells, B cells and memory and naı¨ve
cells) of PBLwere analyzed by flow cytometry according
to our previously published methods [3].
Statistical analysis
Statistical analysis was performed using InStat version
4 (GraphPad Software, San Diego, California, USA).
Normality tests were performed to determine whether
data normally distributed. If data were normally dis-
tributed, then mean values ± SE are shown, pairs of
data were compared using student’s t-test, and ANOVA
was used to compare more than three groups. If anal-
ysis of the group as a whole showed a significant dif-
ference (p < 0.05), then the Bonferroni was used as a
posttest to compare pairs of group. If the data were not
normally distributed, data is presented as median ± in-
terquartile range, pairs of data were compared used the
Mann–Whitney u-test and three or more groups were
compared by Kruskal–Wallis test. Spearman’s rank cor-
relation coefficient test, which gives a Spearman r value,
was performed to assess the degree of correlation be-
tween ADM expression fold-changes with age and gen-
der, and severity of stroke patients at each time point
following stroke. Correlation test and nonlinear regres-
sion (curve fit) were used for analysis of the association
between ADM expression level with NIHSS, mBI and
mRS scores. The slope of the curves of male and female
was compared to determine if there was significant dif-
ference in different gender, or between total stroke and
gender.
Results
Increased ADM gene expression in PBL
of stroke patients compared to controls
ADM expression was examined in the samples col-
lected from patients after stroke, patients with MND
and healthy controls. Since the data were not normally
distributed across all groups, the median fold-changes
were compared between the groups. There was a highly
statistically significant elevation in ADM mRNA levels
at day 1 after stroke compared to healthy controls and
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Figure 1. Fold-change in expression of the ADM gene. Box and
Whisker plots showing fold-change in gene expression of ADM.
Box extends from 25% to 75% percentile, with horizontal line at
median (50% percentile). Whiskers extend down to smallest value
and up to largest value. Stroke samples at all time points showed
significant fold-change compared to healthy controls (HEL) or pa-
tients with MND. ∗∗∗p < 0.001.
patients with MND and this was maintained at week 1
and week 3 (Figure 1). The elevated ADM expression
level in stroke was not affected by gender or age (data
not shown).
ADM expression levels in different
stroke types
Stroke patients were classified according to the Ox-
fordshire Stroke Classification (OSSC) as TACI, PACI,
LACI and POCI [22]. The patients with LACI were ex-
cluded due to small sample size. ADM expression lev-
els in each type of stroke was all significantly different
from healthy controls at three time points; patients with
TACI, the most severe clinical stroke group showed the
greatest increase inADM expression levels at week 1 and
week 3, and these were significantly different to healthy
controls (p < 0.01) (Figure 2).
Correlation of ADM expression with measures
of stroke severity and disability
The severity of stroke was assessed using theNIHSS, the
mBI and themRS for the stroke subjects. Figure 3 shows
that patients with more severe disease and/or greater dis-
ability had significantly high ADM fold-changes at day 1
after stroke (p< 0.006 forNIHSS, r= 0.5553; p= 0.004
formBI, r= 0.5719 and p< 0.001 formRS, r= 0.7023),
and remained high at week 1 (p = 0.006 for NIHSS, r =
0.4665; p < 0.027 for mBI, r = 0.3861 and p = 0.035
for mRS, r= 0.6657). The correlations of stroke severity
Figure 2. ADM gene expression in subjects classed with
OSSC. ADM expression levels in stroke patients at day 1,
week 1 and week 3 (grouped according to OSSC) com-
pared to healthy controls (HEL). Bars represent median ±
interquartile range. Significant differences were found be-
tween stroke groups and healthy controls for each time
point. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. There were
no significant difference when compared within the stroke
groups, for example, between TACI and POCI.




















































Adrenomedullin gene levels and ischemic stroke 5
Figure 3. Correlation of ADM gene expression with NIHSS, mBI and mRS at each time point poststroke. ADM expression levels versus
NIHSS scores, mBI and mRS was significant in stroke day 1 samples and week 1 but not week 3. Statistically significant of the correlations
(the p values) were calculated by Spearman’s rank correlation in GraphPad Prism. The lines, which indicating the trend of the correlation,
were done by nonlinear regression in GraphPad Prism.
with NIHSS, mBI and mRS were also analyzed against
gender (Figures 3 and 4; Tables 2 and 3). The corre-
lations between ADM fold-change and NIHSS, mBI
or mRS in week 3 patients had reduced significance
(Table 2).
Possibility of ADM as a prognosis marker
of stroke
In order to assess if ADM can be a prognostic
biomarker, we correlatedADM expression on day 1 with
the clinical severity score measured on week 1 and 3.
Figure 4 and Table 3 show that ADM expression on day
1 stroke had significant positive correlation with NIHSS
and mRS week 1 and 3 scores, and negative correlation
with mBI. These results indicated severe stroke insult
induces high ADM expression at the earliest stage of
stroke. Alternatively, early ADM expression levels are
correlated to stroke severity and appear prognostic of
longer term disability.
ADM peptide levels
We measured the levels of ADM peptide in the blood of
15 healthy subjects and 21 subjects sampled at day 1,
day 7 and week 3 after stroke. There was no significant
difference between the levels of healthy subjects and pa-
tients with stroke (data not shown).
Flow cytometry analysis
To exclude the possibility that the changes in gene ex-
pression are due to changes in the circulating cell pop-
ulations, we measured the total CD3+ T cells, CD20+
B cells, CD45RO+, CD45RA+ memory and naı¨ve cell
populations (Figure 5). There were no significant differ-
ences between stroke subjects at day 1, week 1 and week
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Figure 4. Correlation of ADM gene expression on day 1 with stroke severity scores on week 1 and week 3. The scores of NIHSS, mBI
and mRS measured at week 1 and week 3 versus ADM expression levels on day 1. Statistically significant of the correlations (the p values)
were calculated by Spearman’s rank correlation in GraphPad Prism. The lines, which indicating the trend of the correlation, were done
by nonlinear regression in GraphPad Prism.
3 stroke compared to healthy controls. There were no
significant differences in DC and NK cell populations
between stroke and healthy controls (data not shown).
Discussion
In this study, we have investigated expression ofADM in
PBLs of subjects with acute ischemic stroke. We studied
the levels of ADM expression over time and also corre-
lated the expression of ADM with severity of stroke. In
accordance with previously published microarray data
[13], we observed an increased ADM gene expression in
PBL of stroke patients using an rtPCR technique. Ex-
amining ADM expression over a 3-week period allowed
the observation of the temporal profile of ADM expres-
sion. Notably, levels remained significantly increased
from day 1 for 3 weeks after stroke, suggesting thatADM
expression occurs as an early event postinsult, and par-
ticipate in the responses induced by stroke over at least
the next three weeks.
It is known that gender and age can influence
gene expression within blood [23]. In our study, these
confounding factors have been excluded through the
Table 2. ADM level versus stroke severity measured on each time point.
Day 1 Week 1 Week 3
Total Female Male Total Female Male Total Female Male
NIHSS
Spearman R 0.555 0.343 0.511 0.467 0.806 0.280 0.253 0.224 0.112
(p value) (0.006) (ns) (ns) (0.006) (0.003) (ns) (ns) (ns) (ns)
mBI
Spearman R −0.572 −0.708 −0.477 −0.386 −0.676 −0.299 −0.391 −0.567 −0.179
(p value) (0.004) (0.033) (ns) (0.027) (0.022) (ns) (0.033) (ns) (ns)
mRS
Spearman R 0.702 0.756 0.662 0.371 0.504 0.344 0.431 0.430 0.337
(p value) (0.001) (0.03) (0.019) (0.037) (ns) (ns) (0.018) (ns) (ns)
ns = not significant
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Table 3. ADM expression level on day 1 versus stroke severity measured on week 1 and week 3.
Day 1/week 1 Day 1/week 3
Total Female Male Total Female Male
NIHSS
Spearman R 0.555 0.343 0.510 0.519 0.633 0.426
(p value) (0.006) (ns) (0.06) (0.048) (ns) (ns)
mBI
Spearman R −0.606 −0.462 −0.442 −0.719 −0.800 −0.623
(p value) (0.004) (0.033) (ns) (0.002) (ns) (0.04)
mRS
Spearman R 0.666 0.671 0.567 0.723 0.872 0.633
(p value) (0.004) (ns) (ns) (0.002) (ns) (0.04)
ns = not significant
correlation of ADM expression levels with the gender
and age of stroke subjects. There was no significant dif-
ference between females and males or any differences
among different age groups of patients.
We have also correlatedADM levels with stroke sever-
ity, measured as NIHSS and patient disability mea-
sured as the mBI and mRS scores. One limitation of the
study is that we chose to analyze the correlation in con-
sider of stroke severity scores as continuous variables,
although these are ordinal variables. There was a sig-
nificant positive correlation on day 1 and week 1 with
NIHSS and mRS, and negative correlation at the same
time points with mBI (Figure 3 and Table 2) poten-
tially indicating thatADM expression occurs as an adap-
tive response to hypoxic tissue injury. Our results found
that the ADM fold-change was influenced by the type
Figure 5 . PBL were labeled with antibodies against CD3, CD20, CD45RO and CD45RA. Each cell population
was tested for their changes using flow cytometry. There were no significant variation in these cell populations at
day 1, week 1 and week 3 strokes.
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of ischemic stroke (Figure 2). It was observed that the
most severe stroke subtype TACI has the highest expres-
sion level at week 1 and week 3 points following stroke
(Figure 2). These results suggested that ADM expres-
sion could be related to stroke severity. Furthermore,
the r values for the ADM levels and stroke severity scores
measured at week 1 and week 3 indicated a strong corre-
lation of ADM level to the stroke severity and disability.
It is possible that the changes in gene expression
in PBL are due to exposure of these cells to hypoxic
environments in the region of the stroke. It has been
reported that ADM expression is regulated by hypoxia
in rat ventricular cardiac myocytes [15], implying tissue
ischemia and inflammation response related activity. Al-
though we have reported that there are increased levels
of activated T cells in subjects with stroke [3,24], there
was no difference in the overall percentages of cell popu-
lations in stroke compared to healthy controls. This sug-
gests that increased ADM gene expression was not af-
fected by variation of cell populations. We do not think
that death of neurons alone is the cause of increased
ADM expression because there was no significant differ-
ence between the subjects with MND, another severely
disabling neurological disease and the healthy controls.
This increased ADM expression could possibly be a
neuro-protective mechanism in line with current litera-
ture [25,26]. A key function of the ADM product is to
produce substantial vasodilation of arterioles [5, 27]. In
an animal model, ADM-induced vasodilation has been
suggested to occur through the binding of the CGRP re-
ceptor and ADM-R [28,29]. ADM has also been shown
to inhibit reactive oxygen species (ROS) in ADMknock-
out heterozygous mice [26]. Additionally, in a rabbit
model, the neuroprotective mechanisms of ADM has
been suggested to function through the cAMP/PKA-
mediated priming of mitochondrial Calcium activated
Potassium (mitoKca) channels [12,26].
There is a need for a biomarker of stroke. The op-
timal blood bio-marker should be rapidly detected, be
sensitive and specific. Thus, far there are over 58 pro-
teins and 7 panels of proteins which have been described
to possess the features to be potential biomarkers for
the diagnosis and prognosis of ischemic stroke [30–33].
However, several studies have described the possibility
of using peripheral blood gene expression in the diag-
nosis in stroke [34–36], and the advantages of using a
RNA biomarker in stroke have also been considered.
Gene transcription is affected by stroke rapidly; it can
occur within minutes, whereas protein translation oc-
curs later than gene transcription. Another reason for
considering marker of gene expression is that, circulat-
ing proteins present detection and accuracy issues [36].
RNA expression in possible ischemic stroke patients has
the potential to yield a sensitive and specific marker for
measurement.
The clinical observation of an early response ADM
expression in our study, has suggested that it could be a
potential bio-marker of ischemic stroke. The correlation
of the ADM expression levels on day 1 with the stroke
severity scores measured on week 1 and week 3 was to
examine if early stroke-induced ADM expression lev-
els can predict disease severity. The results have shown
that high ADM level on day 1 was correlated with worse
stroke (Figure 4 and Table 3).
ADM protein expression has previously been recom-
mended as a biomarker for the other disease [37,38].
However, despite expression levels, we found no signif-
icant difference in levels of ADM peptide in the serum
of subjects with stroke and healthy controls. This could
potentially be due to the rapid degradation or utilization
of ADM in the circulation. Another possibility is that
there are many sources of ADM and increased ADM
produced by hypoxic leukocytes might not be sufficient
to change the overall systemic levels. ADM is released
from pro-ADM, and methods for ADM or pro-ADM
serum levels using radioimmunoassay or an immunolu-
minometric assay have been described [8,9]. It is pos-
sible that pro-ADM measurements may differ between
stroke patients and controls. It would be worth investi-
gation in the future.
Conclusion
The novel contribution of our results to the study of
ADM in ischemic stroke includes the time-course of
ADM expression and correlation with clinical features.
The potential of ADM as a clinical blood prognostic
marker for ischemic stroke was also explored. In sum-
mary, elevated expression of ADM postischemic stroke
was observed, and this was correlated with stroke sever-
ity and disability. Further, there is potential for consider-
ation of ADM expression as a useful clinical biomarker.
Future investigations aim to examine whether hypoxia
is the causative factor in increased ADM expression in
leukocytes postischemic stroke.
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